Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemphire Therapeutics Inc.

Division of NeuroBo Pharmaceuticals Inc.
www.gemphire.com

Latest From Gemphire Therapeutics Inc.

Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs

A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma. 

Financing Deals

Venture Funding Deals: Korean D&D Raises $137.1m For Subsidiary Model

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.

Deals Financing

Novo Carves Deeper Niche Into CV Market With Staten Dyslipidemia Investment

Novo Nordisk is making good on its strategy to prioritize the cardiovascular sector. Its latest deal sees the Danish pharma invest in Staten Biotechnology’s hypertriglyceridemia asset, with potential to acquire the company.

Cardiovascular Deals

Gemphire Reels From Two R&D Blows

A series of setbacks for gemcabene has left the Livonia, MI-based company reeling, but management remains committed to its lead product.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Alias(es)
  • Michigan Life Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NeuroBo Pharmaceuticals Inc.
  • Senior Management
  • Steve Gullans, PhD, CEO
    Charles Bisgaier, PhD, CSO
    Seth Reno, Chief Commercial Officer
  • Contact Info
  • Gemphire Therapeutics Inc.
    Phone: (734) 245-1700
    17199 N. Laurel Park Dr.,
    Ste. 401
    Livonia, MI 48152
    USA
UsernamePublicRestriction

Register